Full-Time

Product and Insights Manager

Clinical Outcomes Assessment

Posted on 8/20/2026

John Wiley & Sons

John Wiley & Sons

51-200 employees

Publishes scientific, technical, and medical literature

Compensation Overview

£53k - £75.9k/yr

Remote in UK + 3 more

More locations: London, UK | Bognor Regis, UK | Oxford, UK

Hybrid

Hybrid work is available in the listed UK locations; the remote option is UK-based. Travel is approximately 10% to 15% per year.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Python
Product Management
SQL

Get referred to John Wiley & Sons

See people who can refer or advise you

Requirements
  • Five or more years of progressive experience in product management, market intelligence, business analysis, commissioning, research, or a comparable analytical and commercially oriented role, with some experience in publishing, healthcare, life sciences, or a research-adjacent environment.
  • Strong analytical capability, including experience working with structured and unstructured data, querying public datasets, and synthesising disparate sources into clear, actionable recommendations.
  • Hands-on capability with technical tooling, including SQL, Python or equivalent, together with working fluency in AI-assisted analytical workflows and judgement about where they add value.
  • A bachelor's degree in a relevant discipline, such as life sciences, data science, business, economics, social sciences, or humanities.
  • A track record of translating analysis into clear, defensible recommendations for senior stakeholders, supported by strong written and verbal communication skills.
  • The ability to scope and prioritise analytical work in an ambiguous, fast-moving environment without prescriptive direction.
  • The ability to influence and inform colleagues without direct authority and to operate with significant autonomy.
  • Sound judgement about which questions matter most, with the discipline to prioritise high-leverage work over interesting but lower-value analysis.
  • The ability to travel primarily for industry conferences, team gatherings, and occasional customer or partner engagement, approximately 10% to 15% per year.
Responsibilities
  • Lead market intelligence and competitive analysis across the Clinical Outcomes Assessment market, tracking competitor offerings, pricing, positioning, regulatory developments, clinical trial patterns, therapeutic area dynamics, and emerging trends.
  • Analyse Wiley's Clinical Outcomes Assessment portfolio against external demand signals, including clinical trial usage data, label claim precedent, regulatory submissions, and competitor catalogues, to identify underleveraged assets, portfolio gaps, and opportunities for acquisition, development, or repositioning.
  • Translate market and portfolio analysis into clear recommendations that inform product roadmap decisions, instrument prioritisation, partnership targeting, and commercial positioning.
  • Build and maintain the datasets, dashboards, and analytical tooling that support ongoing intelligence work, ensuring outputs are reproducible, defensible, and accessible, and applying AI-assisted workflows where they add value.
  • Benchmark competitor pricing, packaging, and positioning to identify pricing opportunities and competitive threats and to support decisions about how Wiley structures, prices, and positions its solutions.
  • Partner across IP and Licensing, Product Delivery, Product, Commercial, and Scientific teams to ensure insight informs decisions across the business, while surfacing emerging market and regulatory signals and contributing to thought leadership where commercially or strategically useful.
Desired Qualifications
  • A master's degree in a relevant discipline.
  • Direct experience with Clinical Outcomes Assessment, electronic Clinical Outcomes Assessment, clinical trials, or health technology assessment ecosystems.
  • Familiarity with clinical trial data sources, including ClinicalTrials.gov, AACT or equivalent, and other public scientific or commercial datasets.
  • Working knowledge of pharmaceutical research and development processes, decision frameworks, and procurement dynamics.
  • Experience with scholarly publishing, rights management, or licensing environments.
  • Experience building proprietary intelligence through web scraping, semantic comparison, or similar data extraction approaches.
  • Experience working in matrixed or cross-functional organisations on commercially material analytical work.

John Wiley & Sons publishes scholarly, professional, and educational content across science, technology, medicine, and the humanities. Its products include textbooks, journals, reference works, and digital resources delivered through the Wiley Online Library and other platforms. Wiley works with authors, editors, and peer reviewers to produce content, then distributes it via print, digital subscriptions, licensing, and open-access options to libraries, universities, researchers, and professionals. The company differentiates itself through a long history as a family-run business spanning six generations, a strategic shift from general printing to science and professional publishing, and a global scale as a publicly traded leader in educational and professional resources. Its goal is to provide reliable, accessible resources that support education, research, and professional development worldwide.

Company Size

51-200

Company Stage

IPO

Headquarters

Hoboken, New Jersey

Founded

1807

Get referred to John Wiley & Sons

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 AI revenue hit $49 million, rising 23% with recurring revenue scaling.
  • Research revenue grew 5%, and article submissions rose 25% in fiscal 2026.
  • Genesis Mission and OpenEvidence partnerships position Wiley inside federal and clinical AI workflows.

What critics are saying

  • The July 2026 False Claims Act suit targets Wiley’s APC pricing model.
  • Ongoing peer-review extortion and 2025 retraction scandals damage editorial credibility and renewals.
  • Learning revenue fell 7% in fiscal 2026; Amazon inventory swings keep pressuring textbook demand.

What makes John Wiley & Sons unique

  • Wiley pairs 200-year publishing trust with AI licensing, Research Exchange, and spectral databases.
  • Emerald added 500 journals and 8,000 books, deepening economics and business ownership.
  • Research Exchange embeds 25-plus integrity checks, plus Imagetwin image screening across 1,500 journals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Professional Development Budget

Company News

Associated Press
Aug 19th, 2026
Wiley launches spectral analysis API portfolio to speed up lab compound identification

Wiley has launched its first spectral analysis API portfolio, allowing laboratories to access its scientific reference databases and analytical tools directly within their own workflows. The APIs enable faster identification and verification of unknown chemical compounds across pharmaceuticals, forensics, environmental science, and other fields. The portfolio includes four core capabilities: spectral database search, spectrum-structure validation, compound classification, and spectra prediction. These tools help labs integrate Wiley's curated spectral data into automated systems, reducing manual effort and analysis time. The APIs address growing demands as sample volumes increase and lab workflows become more software-driven. Unlike fragmented in-house databases, Wiley's solution offers a continuously curated, vendor-neutral foundation supporting multi-technique workflows and regulatory compliance. The launch builds on Wiley's mission to transform knowledge into actionable intelligence for researchers worldwide.

AZoM.com Limited
Aug 12th, 2026
Wiley releases database combining two of the world's most trusted chemical identification resources.

Wiley releases database combining two of the world's most trusted chemical identification resources. Wiley, a global leader in authoritative content and research intelligence, today released the new edition of the Wiley Registry/NIST Mass Spectral Library, a reference database that combines two essential mass spectrometry references in a single, integrated collection, giving scientists the full depth of both to identify unknown chemical compounds. For years, laboratories doing GC-MS analysis have relied on Wiley's renowned Wiley Registry of Mass Spectral Data and the NIST/EPA/NIH EI Mass Spectral Library from the U.S. government's National Institute of Standards and Technology (NIST) to power their analytical workflows. These two respected references are united in this database, one of the most comprehensive resources of its kind. The new 2026 edition updates the collection, adding tens of thousands of newly validated compounds across both libraries and bringing the total to more than 1.2 million electron ionization (EI) mass spectra-unique chemical "signatures" used to identify substances. The Wiley Registry/NIST Mass Spectral Library is part of Wiley's growing portfolio of scientific data and research intelligence solutions, which spans spectral databases, chemistry and materials literature, and analytical tools supporting researchers from discovery through applied outcomes. Wiley's spectral database solutions are trusted by leading pharmaceutical, environmental, and forensic laboratories worldwide, reflecting Wiley's mission to transform knowledge into actionable intelligence that helps researchers make confident, high-stakes decisions. When a scientist runs a sample through a mass spectrometer, the results are only as good as the reference data behind them, By uniting the Wiley Registry and the NIST Library in a single resource, News Medical deliver the breadth, quality, and validation scientists need to identify unknown compounds faster and with confidence." Armughan Rafat, Senior Vice President and Chief AI and Data Analytics Officer, Wiley Available in the most common instrumentation manufacturer formats, the library supports high-confidence analysis across GC-MS workflows. Spectral databases. Spectral databases contain unique molecular "fingerprints" of substances captured through analytical techniques such as infrared (IR), mass spectrometry (MS), nuclear magnetic resonance (NMR), and Raman spectroscopy. By comparing experimental spectra against validated reference data, researchers can accurately identify unknown compounds across a wide range of applications. Be the first to rate this article

Specialty Soya and Grains Alliance
Jul 22nd, 2026
Wiley joins U.S. Department of Energy's Genesis Mission Consortium to advance ai-powered scientific discovery.

Wiley joins U.S. Department of Energy's Genesis Mission Consortium to advance ai-powered scientific discovery. The only scientific publisher in the Consortium, Wiley brings AI-powered research infrastructure, expert-validated workflows, and subject matter expertise to the Mission Wiley today announced its membership in the Genesis Mission Consortium, the public-private partnership supporting the U.S. Department of Energy's (DOE) Genesis Mission, joining organizations including Nvidia, AWS, Microsoft, IBM, and AMD. Wiley is the only scientific publisher among the consortium's members and has been invited to demonstrate its work today at the Genesis Mission Annual Summit in Washington, D.C. The Genesis Mission is a Department of Energy initiative to build the American Science and Security Platform, an AI-driven infrastructure designed to accelerate scientific discovery and harness AI to deliver real-world impact on the most pressing science and technology challenges. Wiley's participation builds on decades of engagement with the DOE and other federal science agencies on research infrastructure. As a consortium member, Wiley plans to make its research intelligence tools available to researchers at all DOE national laboratories and will offer DOE leadership and industry partners an early look at potential applications at today's Summit. Wiley's planned contribution to the Genesis Mission draws on its editorial networks and domain expertise across the sciences and evidence-linked scientific content that supports provenance and reproducibility, alongside operational support to help integrate these capabilities into laboratory environments. "The Genesis Mission is a terrific opportunity for Wiley to apply some of our early breakthrough work in AI and Data Analytics to a program of national importance," said Matthew Kissner, CEO of Wiley. "We are proud to work alongside other members of the Genesis Mission Consortium to help ensure the AI systems shaping science are built on expert-validated workflows and grounded in our rich corpus of authoritative, peer-reviewed content. Accelerating scientific impact requires AI based on trusted evidence - that's the principle behind Wiley's AI platforms, workflows, and partnerships." Founded in 1807, Wiley is the largest U.S. scientific publisher and the world's leading publishing partner to scientific societies, publishing the peer-reviewed research that underpins scientific progress across disciplines and upholding the provenance and credibility of the published scientific record. Wiley's participation in the Genesis Mission Consortium is the latest in a series of global partnerships and initiatives, including collaborations with OpenEvidence, IQVIA, Microsoft, Anthropic, and AWS to bring trusted, peer-reviewed content into leading AI platforms across medicine, life sciences, and research. "Our membership in the Genesis Mission Consortium reflects Wiley's belief that trusted, peer-reviewed content must be at the foundation of any responsible AI infrastructure," said Deirdre Silver, EVP & General Counsel of Wiley. "We're contributing our expertise, the application of trusted scientific knowledge, and the standards and frameworks that will define how science and AI come together to serve the public interest." Leaders and subject matter experts on Wiley's AI & Data Analytics team will participate in Genesis Mission working groups, including those focused on how AI models are validated against scientific evidence and how scientific data is managed. Wiley will also help shape the Consortium's foundational knowledge layer concept, drawing on content and data that are already among the most frequently cited, licensed, and integrated in scientific AI applications worldwide, extending that role into the federal research infrastructure supporting the DOE and its national laboratories. Member News Release submitted by Wiley on 07/22/2026.

Associated Press
Jun 25th, 2026
Wiley raises dividend for 33rd year as AI revenue hits $49M, up 23%

Wiley has raised its quarterly dividend to $0.3575 per share, marking its 33rd consecutive annual increase. The dividend, equivalent to $1.43 per share annually, will be paid on 23 July 2026 to shareholders of record on 7 July 2026. The global research and content company reported strong fiscal 2026 results, including mid-single digit revenue growth in its Research division and a record adjusted operating margin of 17.7%, up 260 basis points. AI revenue reached $49 million, growing 23% year-over-year. Wiley generated $195 million in free cash flow, up 55% from the prior year, and returned $174 million to shareholders through dividends and share repurchases. The company recently acquired Emerald Publishing to expand its research content portfolio.

Yahoo Finance
Jun 16th, 2026
Wiley hits record margins, acquires Emerald Publishing as AI revenue climbs to $49M

Wiley reported record margins and exceptional cash flow growth for fiscal 2026, driven by two reinforcing business segments: research publishing and AI analytics. The company's research division achieved mid-single-digit growth with strong recurring revenue, whilst AI revenue increased from $40 million to $49 million. Interim CEO Matthew Kissner emphasised Wiley's positioning in the AI economy, describing the company's content portfolio as foundational to AI advancement. Following the quarter's close, Wiley completed its largest acquisition since 2007, purchasing Emerald Publishing to expand its proprietary content advantage. The company executed strategic partnerships with IQVIA and Open Evidence and launched Nexus, a content licensing service for publishers. Kissner outlined Wiley's "flywheel" strategy, where research publishing fuels AI growth, which in turn accelerates research capabilities.